FDA Draft Guidance on Gene Editing Safety (2026)
The FDA’s 2026 gene editing draft guidance could change your regulatory strategy. Explore the new NGS requirements for cell and gene editing therapies.
On 14 April 2026, the U.S. Food and Drug Administration (FDA) issued draft guidance establishing standardised next-generation sequencing (NGS) methods for assessing the safety of genome editing therapies.
For sponsors with gene therapy products in development, this is the most operationally significant regulatory document of 2026.
What the FDA's Gene Editing Draft Guidance Covers
The guidance (“Safety Assessment of Genome Editing in Human Gene Therapy Products Using Next-Generation Sequencing”) was issued by the Office of Therapeutic Products (OTP) within the Center for Biologics Evaluation and Research (CBER).
It builds on the January 2024 guidance on human gene therapy products incorporating genome editing, and focuses specifically on NGS-based methods to evaluate off-target editing risks and chromosomal integrity.
The guidance applies to both ex vivo products (where cells are edited outside the body and then reinfused) and in vivo products (where gene editing occurs directly in patient tissues).
This dual scope reflects the full spectrum of cell and gene therapy (CGT) modalities currently in development — from CRISPR-edited T-cell therapies to mRNA-delivered base editing in the liver.
The Core Technical Requirements for Gene Editing Safety
The guidance sets out four areas of technical expectation for sponsors:
- Off-target editing analysis: Sponsors must conduct a complete assessment of unintended editing at sites other than the intended genomic target.
For techniques that cause DNA double-strand breaks (including standard CRISPR-Cas9) the guidance requires a sensitive and quantitative assessment of chromosomal integrity using NGS.
- Sequencing strategy selection: The guidance distinguishes between short-read sequencing (appropriate for evaluating short-stretch DNA changes) and long-read sequencing (required for evaluating longer structural variants).
Sponsors must select and justify their sequencing strategy based on the specific gene editing technique being used.
- Sequencing depth and sensitivity: NGS must be performed at a depth sufficient to detect off-target editing events that typically occur at lower frequencies than the on-target edit rate.
Sponsors must provide data from in-house NGS runs and peer-reviewed publications to support their sensitivity claims.
- Chromosomal translocation reporting: For editing techniques involving double-strand breaks, sponsors must detect and report chromosomal translocation rates between on-target genomic sites using targeted sequencing, primer-based sequencing, or genome-wide NGS methods.
The Bespoke Therapy Framework
This draft guidance is the second regulatory instrument issued under the FDA's broader “plausible mechanism” framework for accelerating bespoke gene therapy development, launched in February 2026.
That framework was designed to formalise a regulatory pathway for individualised therapies targeting ultra-rare diseases, particularly those affecting children, for whom no approved treatments exist.
The framework emerged from the case of baby KJ, a newborn diagnosed with a severe form of carbamoyl-phosphate synthetase 1 (CPS1) deficiency, a rare metabolic disorder causing toxic ammonia accumulation.
Researchers at the Children's Hospital of Philadelphia and the University of Pennsylvania developed a custom CRISPR therapy that successfully edited 42% of liver cells in the patient.
The former FDA Commissioner Martin Makary cited this case as the justification for the new pathway.
The April NGS guidance operationalises the safety assessment component of that pathway. As Commissioner Makary stated at announcement: The FDA is providing sponsors with “clear, scientifically-grounded recommendations for evaluating off-target editing risks using state-of-the-art sequencing technologies.”
What This Means for IND and BLA Submissions
For sponsors preparing Investigational New Drug (IND) applications for genome editing programmes, the draft guidance changes three things:
First, off-target analysis is no longer discretionary.
The guidance makes clear that a complete and sensitive NGS analysis of off-target editing events is a core nonclinical expectation for IND submissions. Sponsors who cannot demonstrate adequate sequencing depth and sensitivity will face additional data requests.
Second, Biologics License Application (BLA) submissions must include NGS-based chromosomal integrity data.
For ex vivo edited cell products and in vivo gene editing programmes, demonstrating chromosomal stability is now an explicit regulatory expectation rather than a recommended best practice.
Third, early regulatory engagement is essential.
The FDA actively encourages sponsors to use INTERACT meetings and pre-Investigational New Drug meetings to discuss NGS strategies before committing to a full nonclinical programme.
Given the technical specificity of the guidance — particularly around sequencing depth and translocation reporting — early alignment with CBER could prevent costly protocol redesigns.
The Importance for Cell and Gene Therapy Leaders
The guidance's scope, covering every genome editing technique, both ex vivo and in vivo, in all tissue types, means it is relevant to virtually every cell and gene therapy programme currently in active development.
CRISPR, base editing, prime editing, and RNA-based editing systems are all impacted.
The most immediate operational implication is analytical development planning. Teams must select NGS platforms and design sequencing strategies that meet the guidance's sensitivity requirements before IND submission.
This is not a standard molecular biology decision. It requires regulatory science expertise in sequencing technology selection and validation.
The guidance also has implications for Chemistry, Manufacturing, and Controls (CMC) strategy. Genomic integrity data from engineering runs must now be generated and documented systematically, not retrospectively.
Process development teams need to understand that NGS data from early manufacturing runs will be submitted alongside clinical data packages.
The comment period closed on 15 June 2026. The docket number is FDA-2026-D-1255. Sponsors with active cell and gene therapy programmes should review the guidance and should have submitted comments to shape the final version, particularly on sequencing depth thresholds and the evidentiary standard for peer-reviewed publication support.
Pharmatica will provide a full regulatory analysis of the finalised guidance when it is published. Pharmatica tracks all FDA, EMA, and International Council for Harmonisation (ICH) developments in cell and gene therapy with the depth and specificity that life sciences executives require.
Pharmatica: Insight. Connection. Impact.
Frequently Asked Questions
What is the FDA's April 2026 gene editing draft guidance?
The FDA's April 2026 draft guidance, titled Safety Assessment of Genome Editing in Human Gene Therapy Products Using Next-Generation Sequencing, sets standardised recommendations for using NGS to evaluate off-target editing events and chromosomal integrity in gene therapy products. It applies to both ex vivo and in vivo gene editing programmes.
What is off-target editing in gene therapy?
Off-target editing is the unintended modification of genomic sites other than the intended therapeutic target. In gene editing techniques that cause DNA double-strand breaks — such as CRISPR-Cas9 — off-target edits can cause chromosomal translocations or disrupt normal cell function, creating potential safety risks that must be characterised before clinical trials begin.
Does the FDA gene editing guidance apply to CRISPR therapies?
Yes. The guidance applies to all genome editing techniques used in human gene therapy products, including CRISPR-Cas9, base editors, prime editors, and RNA-based editing systems. Both ex vivo products (where cells are edited outside the body) and in vivo products (where editing occurs directly in patient tissues) are within scope.
What is the FDA's bespoke therapy framework and how does it relate to the NGS guidance?
The FDA's bespoke therapy framework, launched in February 2026, creates an accelerated regulatory pathway for individualised gene and genome editing therapies targeting ultra-rare diseases. The April 2026 NGS draft guidance is the safety assessment component of that framework, specifying how sponsors must evaluate off-target editing risks in products developed under the new pathway.
How should pharma companies respond to the FDA gene editing draft guidance?
Sponsors with active cell and gene therapy programmes should review the guidance immediately and assess whether their nonclinical NGS strategies meet the specificity requirements for sequencing depth and off-target analysis. Early engagement with the FDA through INTERACT and pre-IND meetings is recommended. Comments were to be submitted to docket FDA-2026-D-1255 before 15 June 2026.
About the author
Did you enjoy the content?
Why not support Nicole Dale by giving this content a like
Comments (0)